Trials / Completed
CompletedNCT02289456
Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2
A Phase II, Single Arm, Open-Label, Multicenter, Safety and Tolerability Trial With Nab-Paclitaxel (ABRAXANE®) Plus Carboplatin Followed by Nab-Paclitaxel Monotherapy as First-Line Treatment for Subjects With Locally Advanced or Metastatic Nonsmall Cell Lung Cancer (NSCLC) and an Eastern Cooperative Oncology Group Performance Status of 2 (ABOUND.PS2)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
4 cycles of induction treatment with nab-paclitaxel and carboplatin followed by nab-paclitaxel monotherapy for those subjects who are progression free at the end of 4 cycles.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | nab-Paclitaxel | |
| DRUG | Carboplatin |
Timeline
- Start date
- 2015-04-28
- Primary completion
- 2017-02-22
- Completion
- 2017-02-22
- First posted
- 2014-11-13
- Last updated
- 2018-12-07
- Results posted
- 2018-04-24
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02289456. Inclusion in this directory is not an endorsement.